226 related articles for article (PubMed ID: 18497862)
21. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
[TBL] [Abstract][Full Text] [Related]
23. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Hart SN; Hoskin T; Shimelis H; Moore RM; Feng B; Thomas A; Lindor NM; Polley EC; Goldgar DE; Iversen E; Monteiro ANA; Suman VJ; Couch FJ
Genet Med; 2019 Jan; 21(1):71-80. PubMed ID: 29884841
[TBL] [Abstract][Full Text] [Related]
25. Characterization of common BRCA1 and BRCA2 variants.
Deffenbaugh AM; Frank TS; Hoffman M; Cannon-Albright L; Neuhausen SL
Genet Test; 2002; 6(2):119-21. PubMed ID: 12215251
[TBL] [Abstract][Full Text] [Related]
26. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
Tram E; Savas S; Ozcelik H
PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
[TBL] [Abstract][Full Text] [Related]
27. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.
Baeyens A; Thierens H; Claes K; Poppe B; de Ridder L; Vral A
Int J Radiat Biol; 2004 Oct; 80(10):745-56. PubMed ID: 15799620
[TBL] [Abstract][Full Text] [Related]
28. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
29. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
[TBL] [Abstract][Full Text] [Related]
30. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
32. BRCA1/2 germline missense mutations: a systematic review.
Corso G; Feroce I; Intra M; Toesca A; Magnoni F; Sargenti M; Naninato P; Caldarella P; Pagani G; Vento A; Veronesi P; Bonanni B; Galimberti V
Eur J Cancer Prev; 2018 May; 27(3):279-286. PubMed ID: 28277317
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I
Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072
[TBL] [Abstract][Full Text] [Related]
34. Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
; ;
Breast Cancer Res Treat; 2008 May; 109(1):67-75. PubMed ID: 17972172
[TBL] [Abstract][Full Text] [Related]
35. Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study.
Garcia AI; Buisson M; Damiola F; Tessereau C; Barjhoux L; Verny-Pierre C; Sornin V; Dondon MG; Eon-Marchais S; ; Caron O; Gautier-Villars M; Coupier I; Buecher B; Vennin P; Belotti M; Lortholary A; Gesta P; Dugast C; Noguès C; Fricker JP; Faivre L; Stoppa-Lyonnet D; Andrieu N; Sinilnikova OM; Mazoyer S
Eur J Hum Genet; 2016 Aug; 24(9):1324-9. PubMed ID: 26785832
[TBL] [Abstract][Full Text] [Related]
36. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors.
Fernández-Ramires R; Gómez G; Muñoz-Repeto I; de Cecco L; Llort G; Cazorla A; Blanco I; Gariboldi M; Pierotti MA; Benítez J; Osorio A
Int J Cancer; 2011 Jun; 128(11):2635-44. PubMed ID: 20715112
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
39. Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation.
Whiley PJ; Parsons MT; Leary J; Tucker K; Warwick L; Dopita B; Thorne H; Lakhani SR; Goldgar DE; Brown MA; Spurdle AB
PLoS One; 2014; 9(1):e86836. PubMed ID: 24489791
[TBL] [Abstract][Full Text] [Related]
40. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]